arrow
G

Giordano Beretta

university hospital of parma
H指数:37
被引数:7,153

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica

不同医院在超说明书用药授权方面的异质性:意大利肿瘤学协会(Associazione Italiana di Oncologia Medica)的项目

2025-10-010
PRE
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (vol 41, 100912, 2024)
2024-09-010
OA
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (Vol 41, 100912, 2024)
2024-07-010
OA
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study
2024-06-012
OAAI
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations

意大利医学肿瘤学协会关于跨性别和性别多样化人群健康差异的立场文件: 阿西西建议

2023-11-017
OAAI
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023-07-013
OAAI
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology

跨性别和性别多样化人群的癌症护理: 意大利医学肿瘤学协会对提供者和医疗服务使用者进行的两次全国性调查的结果

2023-06-0110
OAAI
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)
2022-03-1814
OAAI
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/ IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies
2022-01-0127
PRE
Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper

代谢紊乱和胃肠胰神经内分泌肿瘤 (gep-nets): 它们如何相互影响?意大利医学肿瘤学协会 (AIOM)/意大利医学糖尿病学家协会 (AMD)/意大利内分泌学会 (SIE)/意大利药理学学会 (SIF) 多学科共识立场文件

2022-01-0118
PRE
Nutritional Support in Cancer patients: update of the Italian Intersociety Working Group practical recommendations

癌症患者的营养支持: 意大利社会间工作组实用建议的更新

2022-01-0128
OAAI
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies

实体瘤患者的肿瘤不可知治疗: 代表aiom-siapec/iap-sibioc-sif意大利科学学会的立场文件

2021-09-0118
PRE
Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societa Italiana Endocrinologia (SIE)/Societa Italiana Farmacologia (SIF) multidisciplinary consensus position paper
2021-06-0123
OAAI
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italian Oncologia Medica (AIOM)/Associazione Medici Diabetology (AMD)/Societa Italiana Endocrinologia (SIE)/Societa Italiana Farmacologia (SIF) multidisplinary consensus position paper
2021-06-0120
OAAI
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial

在局部晚期,不可切除的胰腺癌中,Nab-紫杉醇/吉西他滨联合比单独使用吉西他滨更有效-GISCAD II期随机试验

2021-05-019
PREAI
Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcome

在意大利北部新型冠状病毒肺炎大流行的第一个高峰期间,CT与临床和实验室数据相结合的预后价值: 预测不利结果的列线图

2021-04-0116
OAAI